The history of the development and clinical use of CB 3717 and ICI D1694.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Advances in Experimental Medicine and Biology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry, History

• Identifiers
  DOI 10.1007/978-1-4615-2488-5_27PMID 8178723
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Experimental and Clinical Progress in Cancer Chemotherapy

  2011cited by this paper
• The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)

  2004cited by this paper
• The pharmacokinetics of the quinazoline antifolate ICID 1694 in mice and rats

  2004cited by this paper
• Technical Report Abstracts

  1993cited by this paper
• ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.

  1991cited by this paper
• Purine and Pyrimidine Metabolism in Man VII

  1991cited by this paper
• Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications.

  1991cited by this paper
• ICI D1694, an inhibitor of thymidylate synthase for clinical study.

  1991cited by this paper
• The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).

  1991cited by this paper
• Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.

  1990cited by this paper
• Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C2 position.

  1990cited by this paper
• Thymidylate synthase: a target for anticancer drug design.

  1989cited by this paper
• Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency.

  1989cited by this paper
• A phase I evaluation of N10-propargyl-5,8-dideazafolic acid.

  1988cited by this paper
• Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer.

  1988cited by this paper
• Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer.

  1988cited by this paper
• Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717.

  1988cited by this paper
• Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro.

  1988cited by this paper
• Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study.

  1987cited by this paper
• A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.

  1986cited by this paper
• Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma.

  1986cited by this paper
• Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717.

  1986cited by this paper
• Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse.

  1986cited by this paper
• Thymidylate Synthetase Inhibitors: Experimental and Clinical Aspects

  1985cited by this paper
• Activity of the new antifolate N10-propargyl-5,8-dideazafolate and its polyglutamates against human dihydrofolate reductase, human thymidylate synthetase, and KB cells containing different levels of dihydrofolate reductase.

  1985cited by this paper
• Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717.

  1984cited by this paper
• Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.

  1983cited by this paper
• Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase.

  1981cited by this paper
• A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.

  1981cited by this paper
• 2-amino-4-hydroxyquinazolines as inhibitors of thymidylate synthetase.

  1970cited by this paper

• Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor cells.

  2013cites this paper
• Antifolate inhibitors of thymidylate synthase as anticancer drugs.

  2010cites this paper
• Exploitation of the folate receptor in the management of cancer and inflammatory disease.

  2008cites this paper
• Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II.

  2008cites this paper
• Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I.

  2007cites this paper
• Advances in Brief Structural Organization of the Human Folylpoly-y-glutamate Synthetase Gene : Evidence for a Single Genomic Locus '

  2006cites this paper
• Thymidylate synthase inhibitors.

  2006cites this paper
• A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies

  2005cites this paper
• ZD9331: discovery to clinical development

  2005cites this paper
• The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs.

  2004cites this paper
• Antifolates targeted specifically to the folate receptor.

  2004cites this paper
• The Role of α-Folate Receptor-Mediated Transport in the Antitumor Activity of Antifolate Drugs

  2004cites this paper
• ZD9331: discovery to clinical development

  2004cites this paper
• A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies

  2004cites this paper
• TomudexTM (ZD1694): from concept to care, a programme in rational drug discovery

  2004cites this paper
• Raltitrexed (TomudexTM), a Highly Polyglutamatable Antifolate Thymidylate Synthase Inhibitor

  1999cites this paper
• The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (TomudexTM) in a nonhuman primate model

  1999cites this paper
• Antifolate Drugs in Cancer Therapy

  1999cites this paper
• The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice.

  1998cites this paper
• Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.

  1998cites this paper
• Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.

  1997cites this paper
• 'Tomudex' (raltitrexed) development: preclinical, phase I and II studies

  1997cites this paper
• Future challenges in the clinical development of thymidylate synthase inhibitor compounds.

  1997cites this paper
• Reduced pharmacy resource utilization associated with raltitrexed treatment of advanced colorectal cancer

  1997cites this paper
• Quinazoline antifolates thymidylate synthase inhibitors: lipophilic analogues with modification to the C2-methyl substituent.

  1996cites this paper
• Raltitrexed and the treatment of advanced colorectal cancer

  1996cites this paper
• ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.

  1996cites this paper
• Antifolates: current developments.

  1996cites this paper
• Structural organization of the human folypoly-gamma-glutamate synthetase gene: evidence for a single genomic locus.

  1995cites this paper
• Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture.

  1995cites this paper
• ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer.

  1995cites this paper
• Folate-based thymidylate synthase inhibitors as anticancer drugs.

  1995cites this paper
• 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.

  1995cites this paper
• Structural aspects of the inhibition and catalytic mechanism of thymidylate synthase.

  1995cites this paper
• Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.

  1995cites this paper
• Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.

  1995cites this paper